List view / Grid view
VICTRELIS® has received the Prix Galien USA Award for best…
17 October 2012 | By Merck
VICTRELIS® has received the Prix Galien USA Award for best pharmaceutical agent
Merck announced an update on the Phase III trial...
11 July 2012 | By Merck
Merck announced an update on the Phase III trial...
Phenomenex Inc., announces unique new Structure Search functionality...
31 May 2012 | By Phenomenex
Phenomenex Inc., announces unique new Structure Search functionality...
Vintafolide is currently being evaluated in a Phase III clinical…
16 April 2012 | By Merck
Vintafolide is currently being evaluated in a Phase III clinical trial...
Company will review data from TRA-2P and TRACER with external…
7 February 2012 | By Merck
Company will review data from TRA-2P and TRACER with external experts to inform next steps...
Company Confirms Plans to File NDA for Suvorexant in 2012...
6 February 2012 | By Merck
Company Confirms Plans to File NDA for Suvorexant in 2012...
Commits $1.5 billion to R&D in China over the next…
6 December 2011 | By
Commits $1.5 billion to R&D in China over the next 5 years...
TRACER did not achieve primary endpoint...
13 November 2011 | By Merck
TRACER did not achieve primary endpoint...
Merck announced that the CHMP of the EMA has adopted…
20 May 2011 | By Merck
Merck announced that the CHMP of the EMA has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS™...
